Ophthalmic composition for treatment of dry eye disease
AssigneeNovaliq GmbH
InventorsMarkus Beier, Jörg Haisser, Alice Meides, Sonja Krösser, Hartmut Voss, Frank Löscher, Bernhard Günther
Life of this patent
Estimating the term…
Abstract
The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.
Claims16
A method for reducing corneal and/or conjunctival inflammation, the method comprising the step of topically administering to a human patient in need thereof an ophthalmic composition consisting of cyclosporine, 1-perfluorobutylpentane, 2-perfluorobutylpentane, and ethanol;
- wherein the cyclosporine is present in an amount of 0.1% (w/v), the 1-perfluorobutylpentane is present in an amount of at least 97% (w/w), the 2-perfluorobutylpentane is present in an amount of up to 2% (w/w), and the ethanol is present in an amount of up to 1.0% (w/w);
- wherein the composition is administered twice per day per eye as a single drop having a volume of about 10 μl.
Dependencies are inferred from the claim text.